Zanubrutinib versus Fixed-Duration Venetoclax-Ibrutinib Combinations

Dr. Brander discusses the comparison of zanubrutinib from the SEQUOIA trial with fixed-duration venetoclax plus ibrutinib from GLOW and CAPTIVATE studies, examining patient populations and study design relevance. Dr. Shadman explains that this analysis demonstrated comparable efficacy measured by progression-free survival when comparing zanubrutinib to ibrutinib-venetoclax combinations, with more pronounced benefits at three years and beyond, consistent with continuous versus fixed-duration therapy expectations.

The studies had different baseline patient characteristics regarding fitness and age, necessitating adjustment procedures. Despite comparing fixed-duration versus continuous therapy, zanubrutinib demonstrated superior safety profiles compared to ibrutinib plus venetoclax combinations. Dr. Brander notes that GLOW enrolled older patients with more comorbidities while CAPTIVATE included younger, fit patients, with both comparisons showing progression-free survival advantages for continuous therapy, though overall survival differences were not yet observed.

The analysis highlighted methodological challenges with median treatment duration exceeding 43 months for zanubrutinib versus 13.8 months for venetoclax plus ibrutinib combinations. Despite longer exposure, zanubrutinib showed better safety advantages in diarrhea, neutropenia, nausea, anemia, and atrial fibrillation. Dr. Shadman explains this apparent contradiction through cumulative risk analysis: well-tolerated drugs continued longer maintain low cumulative risk despite extended exposure, while combination therapies require intensive monitoring for cytopenias, gastrointestinal toxicities, and treatment interruptions. Patient-reported outcomes and quality-of-life considerations during combination therapy represent important factors not fully captured in safety analyses but crucial for clinical decision-making regarding treatment tolerability and patient experience.